PL2858671T3 - Formulacja przeciwciała - Google Patents

Formulacja przeciwciała

Info

Publication number: PL2858671T3
Authority: PL; Poland
Prior art keywords: antibody formulation; antibody; formulation
Prior art date: 2012-06-12

Application number

PL13744818T

Other languages

English (en)

Inventor

Marta Cosenza

Christoph Stark

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-12

Filing date

2013-06-11

Publication date

2020-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48914378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2858671(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-11 Application filed by Novartis Ag filed Critical Novartis Ag

2020-01-31 Publication of PL2858671T3 publication Critical patent/PL2858671T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL13744818T 2012-06-12 2013-06-11 Formulacja przeciwciała PL2858671T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261658472P	2012-06-12	2012-06-12
PCT/IB2013/054777 WO2013186700A1 (en)	2012-06-12	2013-06-11	Antibody formulation
EP13744818.9A EP2858671B1 (en)	2012-06-12	2013-06-11	Antibody formulation

Publications (1)

Publication Number	Publication Date
PL2858671T3 true PL2858671T3 (pl)	2020-01-31

Family

ID=48914378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13744818T PL2858671T3 (pl)	2012-06-12	2013-06-11	Formulacja przeciwciała

Country Status (37)

Country	Link
US (4)	US9216219B2 (pl)
EP (3)	EP2858671B1 (pl)
JP (1)	JP6265978B2 (pl)
KR (1)	KR102124820B1 (pl)
CN (1)	CN104363920B (pl)
AR (1)	AR091413A1 (pl)
AU (1)	AU2013276112B2 (pl)
BR (1)	BR112014030820B1 (pl)
CA (1)	CA2875386C (pl)
CL (1)	CL2014003370A1 (pl)
CO (1)	CO7151487A2 (pl)
CY (1)	CY1122181T1 (pl)
DK (2)	DK3593814T3 (pl)
EA (1)	EA033373B1 (pl)
EC (1)	ECSP15017314A (pl)
ES (1)	ES2751659T3 (pl)
FI (1)	FI3593814T3 (pl)
GT (1)	GT201400285A (pl)
HR (1)	HRP20191827T1 (pl)
HU (1)	HUE045523T2 (pl)
IL (1)	IL235966B (pl)
LT (2)	LT2858671T (pl)
MA (1)	MA37616A1 (pl)
MX (1)	MX363380B (pl)
MY (1)	MY179818A (pl)
NZ (1)	NZ630885A (pl)
PE (1)	PE20150200A1 (pl)
PH (1)	PH12014502778B1 (pl)
PL (1)	PL2858671T3 (pl)
PT (2)	PT3593814T (pl)
RS (1)	RS67957B1 (pl)
SG (1)	SG11201408174UA (pl)
SI (1)	SI2858671T1 (pl)
TN (1)	TN2014000488A1 (pl)
TW (1)	TWI653983B (pl)
WO (1)	WO2013186700A1 (pl)
ZA (1)	ZA201408547B (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2688093T3 (es)	2010-01-06	2018-10-30	Dyax Corp.	Proteínas de unión a calicreína plasmática
US9458240B2 (en) *	2010-12-10	2016-10-04	Novartis Pharma Ag	Anti-BAFFR antibody formulations
IL269565B2 (en)	2011-01-06	2024-06-01	Dyax Corp	Plasma kallikrein binding proteins
US9216219B2 (en) *	2012-06-12	2015-12-22	Novartis Ag	Anti-BAFFR antibody formulation
TWI595007B (zh)	2012-09-10	2017-08-11	Neotope Biosciences Ltd	抗ｍｃａｍ抗體及相關使用方法
JP2016513682A (ja)	2013-03-15	2016-05-16	ダイアックスコーポレーション	抗血漿カリクレイン抗体
US10513555B2 (en) *	2013-07-04	2019-12-24	Prothena Biosciences Limited	Antibody formulations and methods
CN113350278B (zh)	2013-10-24	2023-03-24	阿斯利康(瑞典)有限公司	稳定的水性抗体配制品
CN104730237A (zh) *	2013-12-23	2015-06-24	国家纳米科学中心	试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法
KR20240049627A (ko)	2014-01-21	2024-04-16	다케다 파머수티컬 컴패니 리미티드	혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
JP2017514458A (ja)	2014-03-12	2017-06-08	プロセナバイオサイエンシーズリミテッド	Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
KR20160127825A (ko)	2014-03-12	2016-11-04	프로테나 바이오사이언시즈 리미티드	항-mcam 항체 및 관련된 사용 방법
EP3122782A4 (en)	2014-03-27	2017-09-13	Dyax Corp.	Compositions and methods for treatment of diabetic macular edema
KR101597037B1 (ko)	2014-06-26	2016-02-24	엘지디스플레이 주식회사	구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치
TWI738632B (zh)	2014-11-07	2021-09-11	瑞士商諾華公司	穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10464999B2 (en)	2015-01-28	2019-11-05	Prothena Biosciences Limited	Anti-transthyretin antibodies
IL254292B2 (en) *	2015-03-30	2026-01-01	Dyax Corp	Plasma kallikrein inhibitors and their uses for preventing the onset of hereditary angioedema
EP3350226A2 (en) *	2015-09-16	2018-07-25	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN108367072B (zh) *	2015-12-07	2022-12-27	默克专利股份有限公司	含抗-pd-l1抗体avelumab的水性药物制剂
BR112018011622A2 (pt)	2015-12-11	2018-11-27	Dyax Corp	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
WO2017104778A1 (ja) *	2015-12-18	2017-06-22	アステラス製薬株式会社	抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
KR102389489B1 (ko) *	2016-06-16	2022-04-22	얀센 백신스 앤드 프리벤션 비.브이.	Hiv 백신 제형
IL326918A (en)	2016-10-19	2026-05-01	Invenra Inc	Antibody structures
JP7681879B2 (ja)	2016-12-22	2025-05-23	ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ	Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
BR112019018022A2 (pt) *	2017-03-01	2020-06-02	Medimmune Limited	Formulações de anticorpos monoclonais
UA129583C2 (uk) *	2017-03-06	2025-06-11	Мерк Патент Гмбх	Водний фармацевтичний склад, який містить антитіло проти pd-l1 авелумаб
US11639391B2 (en) *	2017-04-18	2023-05-02	Dr. Reddy's Laboratories Limited	Stable liquid pharmaceutical composition
JOP20190260A1 (ar) *	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112020001703B1 (pt) *	2017-07-27	2024-01-02	Alexion Pharmaceuticals, Inc	Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
AU2018321335B2 (en) *	2017-08-22	2025-08-14	Biogen Ma Inc.	Pharmaceutical compositions containing anti-beta amyloid antibodies
PE20210042A1 (es)	2017-10-06	2021-01-08	Prothena Biosciences Ltd	Metodos para detectar transtiretina
AU2018375356A1 (en) *	2017-11-29	2020-05-14	Neotope Neuroscience Limited	Lyophilized formulation of a monoclonal antibody against transthyretin
CA3102349A1 (en)	2018-06-05	2019-12-12	King's College London	Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
EP3814373A1 (en)	2018-06-28	2021-05-05	Alexion Pharmaceuticals, Inc.	Methods of producing anti-c5 antibodies
AU2019407063B2 (en) *	2018-12-18	2024-07-04	Novartis Ag	Protein solution formulation containing high concentration of an anti-VEGF antibody
SG11202108627SA (en)	2019-02-18	2021-09-29	Lilly Co Eli	Therapeutic antibody formulation
JP2022521624A (ja) *	2019-02-26	2022-04-11	イノベントバイオロジックス（スウツォウ）カンパニー，リミテッド	抗ｃｄ４７抗体を含む製剤、その調製方法および使用
WO2021091706A1 (en)	2019-11-06	2021-05-14	Novartis Ag	Treatment for sjögren's syndrome
CN113116812A (zh) *	2019-12-30	2021-07-16	百奥泰生物制药股份有限公司	含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
CA3167336A1 (en)	2020-01-13	2021-07-22	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
EP4094777A4 (en) *	2020-01-21	2024-01-24	Innovent Biologics (Suzhou) Co., Ltd.	RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
CN116194478A (zh)	2020-06-24	2023-05-30	阿雷克森制药公司	皮下（sc）施用抗c5抗体治疗补体相关病症
EP4192870A1 (en) *	2020-08-04	2023-06-14	Novartis AG	Treatment of cll
EP4192869A1 (en)	2020-08-04	2023-06-14	Novartis AG	Treatment of b cell malignancies
US20220193238A1 (en) *	2020-12-17	2022-06-23	Astrazeneca Ab	Anti-il5r antibody formulations
CN115073598B (zh) *	2021-03-15	2024-02-20	盛禾(中国)生物制药有限公司	一种抗baffr抗体及其应用
WO2022234439A1 (en)	2021-05-04	2022-11-10	Novartis Ag	Treatment for systemic lupus erythematosus using anti-baffr antibodies
KR20240004760A (ko)	2021-05-04	2024-01-11	노파르티스 아게	항-baffr 항체를 사용한 루푸스 신염의 치료
CN118317975A (zh) *	2021-09-29	2024-07-09	蜻蜓治疗公司	靶向baff-r的抗体及其用途
KR20250120995A (ko)	2022-11-07	2025-08-11	업스트림 바이오, 인크.	항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법
CN118681009A (zh) *	2023-03-21	2024-09-24	百奥泰生物制药股份有限公司	一种复方制剂及其应用
CN116712390B (zh) *	2023-08-04	2023-11-14	上海览屹医药科技有限公司	一种高浓度高稳定性的抗体制剂及其制备方法
WO2025257781A1 (en) *	2024-06-14	2025-12-18	Novartis Ag	Treatment of systemic sclerosis using anti-baff-r antibodies
WO2025263459A1 (ja) *	2024-06-17	2025-12-26	学校法人神戸薬科大学	バイオ医薬品組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0154316B1 (en)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemically modified lymphokine and production thereof
WO1990006952A1 (fr)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US20020077461A1 (en)	1996-04-24	2002-06-20	Soren Bjorn	Pharmaceutical formulation
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
PT1176195E (pt)	1999-04-09	2013-07-18	Kyowa Hakko Kirin Co Ltd	Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CA2375527A1 (en)	1999-06-23	2000-12-28	Oregon Health And Science University	Method for enhancing hematopoiesis
ATE440959T1 (de)	2000-06-28	2009-09-15	Glycofi Inc	Verfahren für die herstellung modifizierter glykoproteine
KR100988949B1 (ko)	2001-10-25	2010-10-20	제넨테크, 인크.	당단백질 조성물
ES2392073T3 (es)	2001-11-08	2012-12-04	Abbott Biotherapeutics Corp.	Formulación farmacéutica líquida estable de anticuerpos IGG
EP1946776B1 (en)	2002-02-27	2017-01-18	Immunex Corporation	Stabilized tnfr-fc composition comprising arginine
US20040191243A1 (en)	2002-12-13	2004-09-30	Bei Chen	System and method for stabilizing antibodies with histidine
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
EA200701211A1 (ru) *	2004-12-31	2007-12-28	Дженентек, Инк.	Полипептиды, которые связываются с br3, и их применение
EA024492B1 (ru) *	2008-07-17	2016-09-30	Новартис Аг	Антитела, специфически связывающиеся с baffr, и их применение
EP2501367B1 (en) *	2009-11-17	2015-01-21	Ipsen Pharma S.A.S.	Formulation for HGH and RHIGF-1 combination
US9458240B2 (en) *	2010-12-10	2016-10-04	Novartis Pharma Ag	Anti-BAFFR antibody formulations
WO2013083497A1 (en)	2011-12-06	2013-06-13	F. Hoffmann-La Roche Ag	Antibody formulation
US9216219B2 (en)	2012-06-12	2015-12-22	Novartis Ag	Anti-BAFFR antibody formulation

2013
- 2013-06-07 US US13/912,355 patent/US9216219B2/en active Active
- 2013-06-10 MA MA37616A patent/MA37616A1/fr unknown
- 2013-06-11 PT PT191858364T patent/PT3593814T/pt unknown
- 2013-06-11 TW TW102120795A patent/TWI653983B/zh active
- 2013-06-11 CA CA2875386A patent/CA2875386C/en active Active
- 2013-06-11 SI SI201331596T patent/SI2858671T1/sl unknown
- 2013-06-11 DK DK19185836.4T patent/DK3593814T3/da active
- 2013-06-11 AU AU2013276112A patent/AU2013276112B2/en active Active
- 2013-06-11 DK DK13744818.9T patent/DK2858671T3/da active
- 2013-06-11 HU HUE13744818A patent/HUE045523T2/hu unknown
- 2013-06-11 EP EP13744818.9A patent/EP2858671B1/en active Active
- 2013-06-11 RS RS20260421A patent/RS67957B1/sr unknown
- 2013-06-11 NZ NZ630885A patent/NZ630885A/en not_active IP Right Cessation
- 2013-06-11 LT LT13744818T patent/LT2858671T/lt unknown
- 2013-06-11 PT PT137448189T patent/PT2858671T/pt unknown
- 2013-06-11 MX MX2014015262A patent/MX363380B/es unknown
- 2013-06-11 MY MYPI2014703690A patent/MY179818A/en unknown
- 2013-06-11 ES ES13744818T patent/ES2751659T3/es active Active
- 2013-06-11 JP JP2015516723A patent/JP6265978B2/ja active Active
- 2013-06-11 PL PL13744818T patent/PL2858671T3/pl unknown
- 2013-06-11 EP EP19185836.4A patent/EP3593814B1/en active Active
- 2013-06-11 HR HRP20191827TT patent/HRP20191827T1/hr unknown
- 2013-06-11 EP EP26152709.7A patent/EP4725556A2/en active Pending
- 2013-06-11 PE PE2014002437A patent/PE20150200A1/es not_active Application Discontinuation
- 2013-06-11 SG SG11201408174UA patent/SG11201408174UA/en unknown
- 2013-06-11 WO PCT/IB2013/054777 patent/WO2013186700A1/en not_active Ceased
- 2013-06-11 EA EA201492292A patent/EA033373B1/ru not_active IP Right Cessation
- 2013-06-11 BR BR112014030820-9A patent/BR112014030820B1/pt active IP Right Grant
- 2013-06-11 LT LTEP19185836.4T patent/LT3593814T/lt unknown
- 2013-06-11 KR KR1020157000336A patent/KR102124820B1/ko active Active
- 2013-06-11 FI FIEP19185836.4T patent/FI3593814T3/fi active
- 2013-06-11 CN CN201380031181.8A patent/CN104363920B/zh active Active
- 2013-06-12 AR ARP130102057 patent/AR091413A1/es not_active Application Discontinuation
2014
- 2014-11-20 ZA ZA2014/08547A patent/ZA201408547B/en unknown
- 2014-11-21 TN TN2014000488A patent/TN2014000488A1/fr unknown
- 2014-11-27 IL IL235966A patent/IL235966B/en active IP Right Grant
- 2014-12-11 PH PH12014502778A patent/PH12014502778B1/en unknown
- 2014-12-11 CL CL2014003370A patent/CL2014003370A1/es unknown
- 2014-12-11 GT GT201400285A patent/GT201400285A/es unknown
- 2014-12-18 CO CO14278419A patent/CO7151487A2/es unknown
2015
- 2015-01-12 EC ECIEPI201517314A patent/ECSP15017314A/es unknown
- 2015-11-16 US US14/942,388 patent/US9751951B2/en active Active
2017
- 2017-08-31 US US15/692,490 patent/US20180051092A1/en not_active Abandoned
2018
- 2018-05-15 US US15/980,411 patent/US10689451B2/en active Active
2019
- 2019-10-22 CY CY20191101096T patent/CY1122181T1/el unknown

Also Published As

Publication number	Publication date
CN104363920B (zh)	2018-05-04
KR102124820B1 (ko)	2020-06-22
US10689451B2 (en)	2020-06-23
ECSP15017314A (es)	2018-06-30
MX363380B (es)	2019-03-21
JP2015521593A (ja)	2015-07-30
LT3593814T (lt)	2026-04-27
EP3593814B1 (en)	2026-01-21
IL235966B (en)	2020-05-31
RS67957B1 (sr)	2026-04-30
IL235966A0 (en)	2015-01-29
DK2858671T3 (da)	2019-10-21
JP6265978B2 (ja)	2018-01-24
TW201402144A (zh)	2014-01-16
TWI653983B (zh)	2019-03-21
PT2858671T (pt)	2019-10-28
EP2858671B1 (en)	2019-07-24
US9216219B2 (en)	2015-12-22
BR112014030820A2 (pt)	2017-07-25
AU2013276112A1 (en)	2014-12-18
GT201400285A (es)	2015-10-15
BR112014030820B1 (pt)	2023-02-07
CA2875386A1 (en)	2013-12-19
KR20150029683A (ko)	2015-03-18
PH12014502778A1 (en)	2015-02-02
CO7151487A2 (es)	2014-12-29
EP2858671A1 (en)	2015-04-15
NZ630885A (en)	2016-01-29
SI2858671T1 (sl)	2019-11-29
US9751951B2 (en)	2017-09-05
CA2875386C (en)	2022-09-13
PH12014502778B1 (en)	2015-02-02
US20180051092A1 (en)	2018-02-22
US20130344088A1 (en)	2013-12-26
MA37616A1 (fr)	2017-08-31
US20160145341A1 (en)	2016-05-26
PT3593814T (pt)	2026-04-14
AU2013276112B2 (en)	2015-07-09
DK3593814T3 (da)	2026-04-27
CY1122181T1 (el)	2020-11-25
ZA201408547B (en)	2015-12-23
AR091413A1 (es)	2015-02-04
EA201492292A1 (ru)	2015-04-30
EP3593814A1 (en)	2020-01-15
HK1203146A1 (en)	2015-10-23
EA033373B1 (ru)	2019-10-31
CL2014003370A1 (es)	2015-02-06
WO2013186700A1 (en)	2013-12-19
CN104363920A (zh)	2015-02-18
HUE045523T2 (hu)	2020-01-28
MY179818A (en)	2020-11-16
EP4725556A2 (en)	2026-04-15
FI3593814T3 (fi)	2026-04-13
ES2751659T3 (es)	2020-04-01
SG11201408174UA (en)	2015-01-29
MX2014015262A (es)	2015-06-23
US20180251564A1 (en)	2018-09-06
HRP20191827T1 (hr)	2019-12-27
TN2014000488A1 (en)	2016-03-30
PE20150200A1 (es)	2015-02-08
LT2858671T (lt)	2019-10-25

Publication	Publication Date	Title
CY2024011I1 (el)	2024-12-13	Αντισωματα anti-fcrn
NL301231I2 (nl)	2023-11-09	Loncastuximab tesirine
DK3593814T3 (da)	2026-04-27	Antistofformulering
DK2890397T3 (da)	2019-08-05	Antiprolactinreceptor-antistofformulering
DK3117837T3 (da)	2019-08-19	Antistofformuleringer
DK3311834T3 (da)	2026-04-20	Formulering til anti-alfa4beta7-antistof
DK2934584T3 (da)	2020-05-18	Anti-gdf15-antistoffer
HRP20181646T1 (hr)	2018-12-14	Konjugati pirolobenzodiazepin - anti-psma protutijela
EP2930240A4 (en)	2016-07-13	ANTI-FOLR1 ANTIBODY
PT2878018T (pt)	2018-02-22	Resumo
PT2819623T (pt)	2018-01-19	Resumo
BR112014025037A2 (pt)	2018-07-31	anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
PT2674413T (pt)	2017-09-18	Resumo
DK2934582T3 (da)	2020-02-24	Anti-her2-antistofformulering
PT2831109T (pt)	2018-02-07	Resumo
PT2825212T (pt)	2018-03-14	Resumo
PT2931313T (pt)	2019-07-10	Formulações de solução de anticorpos anti-il-23p19 modificados
BR112014000015A2 (pt)	2017-02-07	formulação
DK3431504T3 (da)	2021-06-28	Antiphospholipase d4-antistof
DK3521315T3 (da)	2020-11-09	Anti-transglutaminase-2-antistoffer
DK2828292T3 (da)	2019-01-02	Jcv-neutraliserende antistoffer
DK2935330T3 (da)	2019-07-22	Anti-notch3-antistoffer
EP2920370A4 (en)	2016-08-03	POST
EP2770828A4 (en)	2015-04-15	FORMULATION
EP2848633A4 (en)	2015-12-30	ANTI-CXADR ANTIBODY